SCHEMBL6499284

SCHEMBL6499284

CCOc1ccc(-c2ccc(C(F)(F)F)cc2)c(C(=O)Nc2ccc(NCCc3ccccn3)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMO Q99835 2/20 0.49
TRPV1 Q8NER1 3/20 0.47
LMNA P02545 1/20 0.46
TP53 P04637 1/20 0.46
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
KDM4E B2RXH2 2/20 0.45
MITF O75030 1/20 0.45
PKM P14618 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MTTP P55157 2/20 0.43
APOB P04114 1/20 0.43
NR3C1 P04150 2/20 0.43
PPARG P37231 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
NCOR2 Q9Y618 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488795 0.92 SMO (0.50) SMOTRPV1NPC1RAB9ASMN1; SMN2
SCHEMBL6491596 0.92 NPC1 (0.53) SMOTRPV1NPC1RAB9APKM
SCHEMBL6488808 0.91 AURKA (0.49) LMNATP53NPC1RAB9AKDM4E
SCHEMBL6489399 0.91 NPC1 (0.47) LMNATP53NPC1RAB9AKDM4E
SCHEMBL6489529 0.90 AURKA (0.51) TP53NPC1RAB9AKDM4EMITF
SCHEMBL6501416 0.88 SMO (0.51) SMOTRPV1LMNATP53MTTP
SCHEMBL6497909 0.88 SMO (0.52) SMOTRPV1SMN1; SMN2MTTPAPOB
SCHEMBL6491719 0.87 SMO (0.53) SMOTRPV1KDM4EMTTPAPOB
SCHEMBL6492656 0.87 SMO (0.53) SMOTRPV1KDM4ESMN1; SMN2NR3C1
SCHEMBL6498051 0.86 SMO (0.49) SMOTRPV1NPC1RAB9AMTTP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 SMO 2580/4885TRPV1 2245/4885LMNA 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.